Request Free Sample ×
US Obstructive Lung Disease Market Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Obstructive Lung Disease Market

ID: MRFR/Pharma/15193-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

US Obstructive Lung Disease Market Research Report By Disease Type (Asthma, Bronchitis, Copd) and By Product Type (Inhalers, Nebulizers) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Obstructive Lung Disease Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Type (USD Billion)
  49.     4.1.1 Asthma
  50.     4.1.2 Bronchiectasis
  51.     4.1.3 Bronchitis
  52.     4.1.4 Chronic Obstructive Pulmonary Disease (COPD)
  53.     4.1.5 Others
  54.   4.2 Pharmaceutical, BY Product Type (USD Billion)
  55.     4.2.1 Inhalers
  56.     4.2.2 Nebulizers
  57.     4.2.3 Others
  58.   4.3 Pharmaceutical, BY Drug Class (USD Billion)
  59.     4.3.1 Combination Drugs
  60.     4.3.2 Leukotriene Antagonists (LTA)
  61.     4.3.3 Inhaled Corticosteroids (ICS)
  62.     4.3.4 Anticholinergics
  63.     4.3.5 Short Acting Beta Agonists (SABA)
  64.     4.3.6 Long Acting Beta Agonists (LABA)
  65.     4.3.7 Others
  66.   4.4 Pharmaceutical, BY Route of Administration (USD Billion)
  67.     4.4.1 Oral
  68.     4.4.2 Inhaler
  69.     4.4.3 Intravenous
  70.     4.4.4 Subcutaneous
  71.     4.4.5 Others
  72.   4.5 Pharmaceutical, BY End-User (USD Billion)
  73.     4.5.1 Hospitals & Diagnostic Centers
  74.     4.5.2 Academic Institutes
  75.     4.5.3 Pharmaceutical & Biotechnology Companies
  76.     4.5.4 Others
  77. 5 SECTION V: COMPETITIVE ANALYSIS
  78.   5.1 Competitive Landscape
  79.     5.1.1 Overview
  80.     5.1.2 Competitive Analysis
  81.     5.1.3 Market share Analysis
  82.     5.1.4 Major Growth Strategy in the Pharmaceutical
  83.     5.1.5 Competitive Benchmarking
  84.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  85.     5.1.7 Key developments and growth strategies
  86.       5.1.7.1 New Product Launch/Service Deployment
  87.       5.1.7.2 Merger & Acquisitions
  88.       5.1.7.3 Joint Ventures
  89.     5.1.8 Major Players Financial Matrix
  90.       5.1.8.1 Sales and Operating Income
  91.       5.1.8.2 Major Players R&D Expenditure. 2023
  92.   5.2 Company Profiles
  93.     5.2.1 GlaxoSmithKline (GB)
  94.       5.2.1.1 Financial Overview
  95.       5.2.1.2 Products Offered
  96.       5.2.1.3 Key Developments
  97.       5.2.1.4 SWOT Analysis
  98.       5.2.1.5 Key Strategies
  99.     5.2.2 Boehringer Ingelheim (DE)
  100.       5.2.2.1 Financial Overview
  101.       5.2.2.2 Products Offered
  102.       5.2.2.3 Key Developments
  103.       5.2.2.4 SWOT Analysis
  104.       5.2.2.5 Key Strategies
  105.     5.2.3 AstraZeneca (GB)
  106.       5.2.3.1 Financial Overview
  107.       5.2.3.2 Products Offered
  108.       5.2.3.3 Key Developments
  109.       5.2.3.4 SWOT Analysis
  110.       5.2.3.5 Key Strategies
  111.     5.2.4 Novartis (CH)
  112.       5.2.4.1 Financial Overview
  113.       5.2.4.2 Products Offered
  114.       5.2.4.3 Key Developments
  115.       5.2.4.4 SWOT Analysis
  116.       5.2.4.5 Key Strategies
  117.     5.2.5 Teva Pharmaceutical Industries (IL)
  118.       5.2.5.1 Financial Overview
  119.       5.2.5.2 Products Offered
  120.       5.2.5.3 Key Developments
  121.       5.2.5.4 SWOT Analysis
  122.       5.2.5.5 Key Strategies
  123.     5.2.6 Mylan (US)
  124.       5.2.6.1 Financial Overview
  125.       5.2.6.2 Products Offered
  126.       5.2.6.3 Key Developments
  127.       5.2.6.4 SWOT Analysis
  128.       5.2.6.5 Key Strategies
  129.     5.2.7 Roche (CH)
  130.       5.2.7.1 Financial Overview
  131.       5.2.7.2 Products Offered
  132.       5.2.7.3 Key Developments
  133.       5.2.7.4 SWOT Analysis
  134.       5.2.7.5 Key Strategies
  135.     5.2.8 Sanofi (FR)
  136.       5.2.8.1 Financial Overview
  137.       5.2.8.2 Products Offered
  138.       5.2.8.3 Key Developments
  139.       5.2.8.4 SWOT Analysis
  140.       5.2.8.5 Key Strategies
  141.     5.2.9 Pfizer (US)
  142.       5.2.9.1 Financial Overview
  143.       5.2.9.2 Products Offered
  144.       5.2.9.3 Key Developments
  145.       5.2.9.4 SWOT Analysis
  146.       5.2.9.5 Key Strategies
  147.   5.3 Appendix
  148.     5.3.1 References
  149.     5.3.2 Related Reports
  150. 6 LIST OF FIGURES
  151.   6.1 MARKET SYNOPSIS
  152.   6.2 US MARKET ANALYSIS BY TYPE
  153.   6.3 US MARKET ANALYSIS BY PRODUCT TYPE
  154.   6.4 US MARKET ANALYSIS BY DRUG CLASS
  155.   6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  156.   6.6 US MARKET ANALYSIS BY END-USER
  157.   6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
  158.   6.8 RESEARCH PROCESS OF MRFR
  159.   6.9 DRO ANALYSIS OF PHARMACEUTICAL
  160.   6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  161.   6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  162.   6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  163.   6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
  164.   6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Billion)
  165.   6.15 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 (% SHARE)
  166.   6.16 PHARMACEUTICAL, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
  167.   6.17 PHARMACEUTICAL, BY DRUG CLASS, 2024 (% SHARE)
  168.   6.18 PHARMACEUTICAL, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
  169.   6.19 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  170.   6.20 PHARMACEUTICAL, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  171.   6.21 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
  172.   6.22 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Billion)
  173.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  174. 7 LIST OF TABLES
  175.   7.1 LIST OF ASSUMPTIONS
  176.     7.1.1
  177.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  178.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  179.     7.2.2 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  180.     7.2.3 BY DRUG CLASS, 2025-2035 (USD Billion)
  181.     7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  182.     7.2.5 BY END-USER, 2025-2035 (USD Billion)
  183.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  184.     7.3.1
  185.   7.4 ACQUISITION/PARTNERSHIP
  186.     7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Billion, 2025-2035)

  • Asthma
  • Bronchiectasis
  • Bronchitis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

Pharmaceutical By Product Type (USD Billion, 2025-2035)

  • Inhalers
  • Nebulizers
  • Others

Pharmaceutical By Drug Class (USD Billion, 2025-2035)

  • Combination Drugs
  • Leukotriene Antagonists (LTA)
  • Inhaled Corticosteroids (ICS)
  • Anticholinergics
  • Short Acting Beta Agonists (SABA)
  • Long Acting Beta Agonists (LABA)
  • Others

Pharmaceutical By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Inhaler
  • Intravenous
  • Subcutaneous
  • Others

Pharmaceutical By End-User (USD Billion, 2025-2035)

  • Hospitals & Diagnostic Centers
  • Academic Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓